Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

Posted:
17
August 2020

Richmond Pharmacology early phase drug development update.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Alnylam's lumasiran a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

The decision allows patients with the ultra-rare disease primary hyperoxaluria type 1 (PH1) access to the drug before its official approval by the European Commission.

PH1 is an ultra-rare orphan disease affecting around 90 patients in the UK, that causes an abnormal build-up of toxic oxalate in the liver, resulting in painful and recurrent kidney stones and ultimately irreparable damage to the kidneys and other vital organs.

Richmond Pharmacology is proud to have been involved in the early stage of the drug and supported the development through a first-in-human combined healthy volunteer and patient trial.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more